U.S. FDA panel recommends Ferring's fecal transplant therapy [Reuters]
Seres Therapeutics, Inc. (MCRB)
Last seres therapeutics, inc. earnings: 11/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.serestherapeutics.com
Company Research
Source: Reuters
The therapy is based on the concept of replenishing the good gut bacteria through samples of microbes distilled from faeces of healthy donors, delivered through an enema in this case. Besides Switzerland-based Ferring, other companies including Seres Therapeutics (MCRB.O) are working on similar therapies based on fecal microbiota transplantation (FMT), as well as synthetically fermented versions. While no FMT therapy has yet been approved by the FDA, it has been widely used for patients with recurring C. diff infections under the agency's "enforcement discretion" provision. Ferring says that access through that pathway to FMT therapies, however, remains limited, and is not standardized. Privately-held Ferring acquired the drug through its 2018 purchase of U.S.-based Rebiotix Inc. Reporting by Manas Mishra and Raghav Mahobe in Bengaluru; Editing by Shinjini Ganguli Our Standards: The Thomson Reuters Trust Principles.
Show less
Read more
Impact Snapshot
Event Time:
MCRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MCRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MCRB alerts
High impacting Seres Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MCRB
News
- Increases to Seres Therapeutics, Inc.'s (NASDAQ:MCRB) CEO Compensation Might Cool off for now [Yahoo! Finance]Yahoo! Finance
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Microbiome Manufacturing Market Trends and Global Forecasts, 2035 - Close to 170 Trials are Evaluating Microbiome Therapeutics to Treat Various Infectious Diseases and Oncological Disorders [Yahoo! Finance]Yahoo! Finance
- Seres Therapeutics, Inc. (NASDAQ: MCRB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $9.00 to $5.00. They now have an "outperform" rating on the stock.MarketBeat
MCRB
Earnings
- 11/2/23 - Beat
MCRB
Sec Filings
- 3/27/24 - Form 4
- 3/27/24 - Form 3
- 3/5/24 - Form DEF
- MCRB's page on the SEC website